Interleukin-1α neutralisation in patients with cancer

Affiliations

¹ Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA; Department of Medicine, Radboud University Medical Center, Nijmegen, HB 6500, Netherlands. Electronic address: charles.dinarello@ucdenver.edu.

Comment

Charles Anthony Dinarello. Lancet Oncol. 2014 May.

. 2014 May;15(6):552-3.

doi: 10.1016/S1470-2045(14)70164-0. Epub 2014 Apr 17.

¹ Department of Medicine, University of Colorado Denver, Aurora, CO 80045, USA; Department of Medicine, Radboud University Medical Center, Nijmegen, HB 6500, Netherlands. Electronic address: charles.dinarello@ucdenver.edu.

No abstract available

Comment on

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.
Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R. Hong DS, et al. Lancet Oncol. 2014 May;15(6):656-66. doi: 10.1016/S1470-2045(14)70155-X. Epub 2014 Apr 17. Lancet Oncol. 2014. PMID: 24746841 Clinical Trial.